Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2019 May 1;17(5):479-505.
doi: 10.6004/jnccn.2019.0023.

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

James L Mohler  1 , Emmanuel S Antonarakis  2 , Andrew J Armstrong  3 , Anthony V D'Amico  4 , Brian J Davis  5 , Tanya Dorff  6 , James A Eastham  7 , Charles A Enke  8 , Thomas A Farrington  9 , Celestia S Higano  10 , Eric Mark Horwitz  11 , Michael Hurwitz  12 , Joseph E Ippolito  13 , Christopher J Kane  14 , Michael R Kuettel  1 , Joshua M Lang  15 , Jesse McKenney  16 , George Netto  17 , David F Penson  18 , Elizabeth R Plimack  11 , Julio M Pow-Sang  19 , Thomas J Pugh  20 , Sylvia Richey  21 , Mack Roach  22 , Stan Rosenfeld  22 , Edward Schaeffer  23 , Ahmad Shabsigh  24 , Eric J Small  22 , Daniel E Spratt  25 , Sandy Srinivas  26 , Jonathan Tward  27 , Dorothy A Shead  28 , Deborah A Freedman-Cass  28
Affiliations
Practice Guideline

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

James L Mohler et al. J Natl Compr Canc Netw. .

Abstract

The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options for localized disease, and management of recurrent and advanced disease for clinicians who treat patients with prostate cancer. The portions of the guidelines included herein focus on the roles of germline and somatic genetic testing, risk stratification with nomograms and tumor multigene molecular testing, androgen deprivation therapy, secondary hormonal therapy, chemotherapy, and immunotherapy in patients with prostate cancer.

PubMed Disclaimer

Publication types